Published in Stroke on October 15, 2009
The science of stroke: mechanisms in search of treatments. Neuron (2010) 6.14
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA (2014) 3.86
Animal models of traumatic brain injury. Nat Rev Neurosci (2013) 2.75
High plasma erythropoietin levels are associated with prolonged coma duration and increased mortality in children with cerebral malaria. Clin Infect Dis (2014) 2.02
High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol (2013) 1.75
Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis (2012) 1.69
Stroke research at a crossroad: asking the brain for directions. Nat Neurosci (2011) 1.68
Angiogenesis, neurogenesis and brain recovery of function following injury. Curr Opin Investig Drugs (2010) 1.67
The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol Sci (2012) 1.66
Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation. Lancet Neurol (2012) 1.60
Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro (2012) 1.50
Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models. J Physiol (2011) 1.46
Neuroplasticity in the context of motor rehabilitation after stroke. Nat Rev Neurol (2011) 1.45
Effects of combination of proliferative agents and erythropoietin on left ventricular remodeling post-myocardial infarction. Clin Transl Sci (2011) 1.43
Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial. Crit Care (2015) 1.42
A concerted appeal for international cooperation in preclinical stroke research. Stroke (2013) 1.32
Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neurotrauma Pharmacology Workgroup. J Neurotrauma (2014) 1.31
Erythropoietin. Cold Spring Harb Perspect Med (2013) 1.28
Neuroprotection by dimethyloxalylglycine following permanent and transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab (2010) 1.27
Targeting astrocytes for stroke therapy. Neurotherapeutics (2010) 1.25
Angiogenesis: a harmonized target for recovery after stroke. Stroke (2012) 1.22
Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke. Crit Care (2011) 1.22
Physiology and pharmacology of erythropoietin. Transfus Med Hemother (2013) 1.21
Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. Expert Rev Anti Infect Ther (2010) 1.20
Stem cell-based therapies for ischemic stroke. Biomed Res Int (2014) 1.19
Effects of recombinant human erythropoietin in normal humans. J Physiol (2010) 1.12
Cerebral blood flow alteration in neuroprotection following cerebral ischaemia. J Physiol (2011) 1.11
Dose-dependent neurorestorative effects of delayed treatment of traumatic brain injury with recombinant human erythropoietin in rats. J Neurosurg (2011) 1.10
Neuroprotective Strategies during Cardiac Surgery with Cardiopulmonary Bypass. Int J Mol Sci (2016) 1.08
Back to the ground. Stroke (2010) 1.07
Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes (2011) 1.06
Synergistic neuroprotective therapies with hypothermia. Semin Fetal Neonatal Med (2010) 1.05
Stem cells and stroke: opportunities, challenges and strategies. Expert Opin Biol Ther (2011) 1.04
Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci (2012) 1.04
Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke. Stroke (2010) 1.03
Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care (2011) 1.03
Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. Ann Med (2010) 1.02
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J (2010) 1.00
Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke. Prog Neurobiol (2015) 0.99
The effect of erythropoietin on normal and neoplastic cells. Biologics (2012) 0.98
Hyperglycemia, acute ischemic stroke, and thrombolytic therapy. Transl Stroke Res (2014) 0.95
Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Mol Med (2011) 0.94
Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol (2012) 0.94
Neurorestorative treatments for traumatic brain injury. Discov Med (2010) 0.94
Pharmacological neuroprotection after perinatal hypoxic-ischemic brain injury. Curr Neuropharmacol (2010) 0.93
Collateral Circulation in Ischemic Stroke: Assessment Tools and Therapeutic Strategies. Stroke (2015) 0.93
Cerebral tissue repair and atrophy after embolic stroke in rat: a magnetic resonance imaging study of erythropoietin therapy. J Neurosci Res (2010) 0.93
Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? J Investig Med (2011) 0.92
Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses. Front Cell Neurosci (2013) 0.92
Thrombopoietin protects the brain and improves sensorimotor functions: reduction of stroke-induced MMP-9 upregulation and blood-brain barrier injury. J Cereb Blood Flow Metab (2010) 0.92
Erythropoietin improves long-term outcomes in patients with acute kidney injury after coronary artery bypass grafting. J Korean Med Sci (2012) 0.91
Impact of erythropoietin on intensive care unit patients. Transfus Med Hemother (2013) 0.91
Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci (2014) 0.91
Erythropoietin for stroke treatment: dead or alive? Crit Care (2011) 0.90
Erythropoietin: still on the neuroprotection road. Ther Adv Neurol Disord (2012) 0.90
Trophic factors and cell therapy to stimulate brain repair after ischaemic stroke. J Cell Mol Med (2012) 0.90
Pharmacologic preconditioning: translating the promise. Transl Stroke Res (2010) 0.89
Statins and anti-inflammatory therapies for subarachnoid hemorrhage. Curr Treat Options Neurol (2012) 0.89
Advances in stroke therapy. Drug Deliv Transl Res (2011) 0.88
Mutant erythropoietin without erythropoietic activity is neuroprotective against ischemic brain injury. Stroke (2012) 0.88
Cell-based therapy for ischemic stroke. Expert Opin Biol Ther (2013) 0.87
Combination of cyclosporine and erythropoietin improves brain infarct size and neurological function in rats after ischemic stroke. J Transl Med (2011) 0.87
Erythropoietin: powerful protection of ischemic and post-ischemic brain. Exp Biol Med (Maywood) (2014) 0.87
Intracranial hemorrhage. Am J Respir Crit Care Med (2011) 0.86
Finding an optimal rehabilitation paradigm after stroke: enhancing fiber growth and training of the brain at the right moment. Front Hum Neurosci (2014) 0.86
Erythropoietin in brain development and beyond. Anat Res Int (2012) 0.86
Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims. Transl Stroke Res (2011) 0.85
Hydrogel-delivered brain-derived neurotrophic factor promotes tissue repair and recovery after stroke. J Cereb Blood Flow Metab (2016) 0.85
Human erythropoietin effect in postoperative visual loss following spine surgery: a case report. Anesth Pain Med (2014) 0.85
Emergent properties of neural repair: elemental biology to therapeutic concepts. Ann Neurol (2016) 0.84
The neurobiology of erythropoietin. Cell Mol Neurobiol (2011) 0.84
New antioxidant drugs for neonatal brain injury. Oxid Med Cell Longev (2015) 0.84
Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials (2010) 0.84
A single topical dose of erythropoietin applied on a collagen carrier enhances calvarial bone healing in pigs. Acta Orthop (2014) 0.83
Non-erythroid effects of erythropoietin. Haematologica (2010) 0.83
A Distinct Region in Erythropoietin that Induces Immuno/Inflammatory Modulation and Tissue Protection. Neurotherapeutics (2015) 0.83
Vascular protection to increase the safety of tissue plasminogen activator for stroke. Curr Pharm Des (2012) 0.83
The rostral migratory stream plays a key role in intranasal delivery of drugs into the CNS. PLoS One (2011) 0.83
Testing cardiovascular drug safety and efficacy in randomized trials. Circ Res (2014) 0.82
Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke. Neurochem Res (2013) 0.82
Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now. Transl Stroke Res (2013) 0.82
Potential of Novel EPO Derivatives in Limb Ischemia. Cardiol Res Pract (2012) 0.81
Growth factors for the treatment of ischemic brain injury (growth factor treatment). Brain Sci (2015) 0.81
Darbepoetin Administration in Term and Preterm Neonates. Clin Perinatol (2015) 0.80
Molecular mechanisms of ischemic preconditioning in the kidney. Am J Physiol Renal Physiol (2015) 0.80
Recombinant human erythropoietin increases cerebral cortical width index and neurogenesis following ischemic stroke. Neural Regen Res (2012) 0.80
Highly efficient differentiation of neural precursors from human embryonic stem cells and benefits of transplantation after ischemic stroke in mice. Stem Cell Res Ther (2013) 0.80
Bench-to-bedside review: Erythropoietin and its derivatives as therapies in critical care. Crit Care (2012) 0.80
Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. Mov Disord (2011) 0.79
Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues. PLoS One (2015) 0.79
Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain stroke. Drug Deliv Transl Res (2013) 0.79
The mitochondria-targeted antioxidants and remote kidney preconditioning ameliorate brain damage through kidney-to-brain cross-talk. PLoS One (2012) 0.79
Cardiovascular effects of erythropoietin an update. Adv Pharmacol (2010) 0.79
Erythropoietin: recent developments in the treatment of spinal cord injury. Neurol Res Int (2011) 0.79
Targeting glia for treatment of neurological disease. Neurotherapeutics (2010) 0.79
Different expression patterns of Ngb and EPOR in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of Neuro-EPO for ischemic insults to the gerbil brain. J Histochem Cytochem (2011) 0.78
The beta-hCG+erythropoietin in acute stroke (BETAS) study: a 3-center, single-dose, open-label, noncontrolled, phase IIa safety trial. Stroke (2010) 0.78
Spatial distribution of insulin-like growth factor binding protein-2 following hypoxic-ischemic injury. BMC Neurosci (2013) 0.78
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology (2002) 7.53
Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol (2007) 6.15
Comparison of the most favoured methods for the diagnosis of hepatic encephalopathy in liver transplantation candidates. Gut (2013) 4.07
Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol (2008) 3.98
Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol (2007) 3.96
Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med (2002) 3.87
Statistical analysis of the primary outcome in acute stroke trials. Stroke (2012) 3.52
Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol (2009) 3.36
The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest (2005) 3.22
Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke (2008) 3.21
Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke (2004) 3.07
Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology (2013) 2.99
A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke (2009) 2.80
Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging (2013) 2.56
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (2014) 2.56
Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke (2007) 2.56
Intravenous brain-derived neurotrophic factor enhances poststroke sensorimotor recovery and stimulates neurogenesis. Stroke (2007) 2.54
MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol (2006) 2.42
Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci (2004) 2.36
Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol (2014) 2.36
Hyperglycemia after SAH: predictors, associated complications, and impact on outcome. Stroke (2005) 2.36
Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke (2013) 2.36
Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke (2007) 2.36
Comparison of CT and CT angiography source images with diffusion-weighted imaging in patients with acute stroke within 6 hours after onset. Stroke (2002) 2.33
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology (2013) 2.26
Acute stroke triage to intravenous thrombolysis and other therapies with advanced CT or MR imaging: pro MR imaging. Radiology (2009) 2.23
Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain (2008) 2.18
Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One (2010) 2.15
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol (2003) 2.14
MR mismatch is useful for patient selection for thrombolysis: yes. Stroke (2009) 2.13
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2011) 2.12
β-synuclein aggregates and induces neurodegeneration in dopaminergic neurons. Ann Neurol (2013) 2.10
Air quality, stroke, and coronary events: results of the Heinz Nixdorf Recall Study from the Ruhr Region. Dtsch Arztebl Int (2015) 2.10
Asymmetric dimethylarginine in response to recombinant tissue-type plasminogen activator and erythropoietin in acute stroke. Stroke (2013) 2.07
Systematic review of early recurrent stenosis after carotid angioplasty and stenting. Stroke (2004) 2.04
An optical coherence tomography study on degeneration of retinal nerve fiber layer in rats with autoimmune optic neuritis. Invest Ophthalmol Vis Sci (2012) 2.02
New brain lesions after carotid stenting versus carotid endarterectomy: a systematic review of the literature. Stroke (2008) 1.91
Genome of Herbaspirillum seropedicae strain SmR1, a specialized diazotrophic endophyte of tropical grasses. PLoS Genet (2011) 1.91
Stroke MRI in intracerebral hemorrhage: is there a perihemorrhagic penumbra? Stroke (2003) 1.90
Origin and temperature dependence of radiation damage in biological samples at cryogenic temperatures. Proc Natl Acad Sci U S A (2009) 1.88
ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain (2007) 1.87
Intra- and interrater reliability of ischemic lesion volume measurements on diffusion-weighted, mean transit time and fluid-attenuated inversion recovery MRI. Stroke (2006) 1.77
Effects of hypertonic (10%) saline in patients with raised intracranial pressure after stroke. Stroke (2002) 1.73
Mechanisms of acute axonal degeneration in the optic nerve in vivo. Proc Natl Acad Sci U S A (2010) 1.70
Incidental effects of emotional valence in single word processing: an fMRI study. Neuroimage (2005) 1.69
Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery (2006) 1.68
Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem (2011) 1.64
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. Stroke (2008) 1.62
Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke (2009) 1.61
Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J Neurochem (2007) 1.59
Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke (2006) 1.59
Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci (2010) 1.59
Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke (2004) 1.58
Lack of the Kir4.1 channel subunit abolishes K+ buffering properties of astrocytes in the ventral respiratory group: impact on extracellular K+ regulation. J Neurophysiol (2005) 1.57
A risk score to predict ischemic lesions after protected carotid artery stenting. J Neurol Sci (2008) 1.57
Bilateral thalamic infarction--a rare manifestation of dural venous sinus thrombosis. Clin Imaging (2010) 1.57
Changes of resting state brain networks in amyotrophic lateral sclerosis. Exp Neurol (2009) 1.56
Differential recovery of behavioral status and brain function assessed with functional magnetic resonance imaging after mild traumatic brain injury in the rat. Crit Care Med (2007) 1.56
Local intra-arterial fibrinolysis of thromboemboli occurring during neuroendovascular procedures with recombinant tissue plasminogen activator. Stroke (2003) 1.55
Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol (2006) 1.55
Posterior reversible encephalopathy syndrome. J Intensive Care Med (2011) 1.55
Reliability of brain CT evaluation by stroke neurologists in telemedicine. Neurology (2012) 1.54
Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol (2009) 1.52
Therapy of acute basilar artery occlusion: intraarterial thrombolysis alone vs bridging therapy. Stroke (2008) 1.52
Endotoxin reduces availability of voltage-gated human skeletal muscle sodium channels at depolarized membrane potentials. Crit Care Med (2008) 1.51
Bond orders and atomic properties of the highly deformed halogenated fullerenes C60F18 and C60Cl30 derived from their charge densities. Chemistry (2007) 1.50
Weight approximation in stroke before thrombolysis: the WAIST-Study: a prospective observational "dose-finding" study. Stroke (2010) 1.48
Embolic inner ear decompression illness: correlation with a right-to-left shunt. Laryngoscope (2003) 1.48
Acute Stroke Imaging Research Roadmap II. Stroke (2013) 1.47
Triple stimulation technique (TST) in amyotrophic lateral sclerosis. Clin Neurophysiol (2004) 1.47
Acute mountain sickness: controversies and advances. High Alt Med Biol (2004) 1.46
Dose effect of intraventricular fibrinolysis in ventricular hemorrhage. Stroke (2011) 1.45
Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol (2004) 1.45
Autonomic function and cerebral autoregulation in patients undergoing carotid endarterectomy. Circ J (2010) 1.45
Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest Ophthalmol Vis Sci (2004) 1.44
Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke (2012) 1.43
Correlation between automated writing movements and striatal dopaminergic innervation in patients with Wilson's disease. J Neurol (2002) 1.43
Late in-stent thrombosis following carotid angioplasty and stenting. Neurology (2006) 1.42
Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain (2007) 1.42
Functional significance of age-related differences in motor activation patterns. Neuroimage (2006) 1.41
Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord (2007) 1.41
TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol (2006) 1.41
Comparison of ABC/2 estimation technique to computer-assisted planimetric analysis in warfarin-related intracerebral parenchymal hemorrhage. Stroke (2005) 1.41